Moleculin Biotech Inc (NASDAQ: MBRX) shares leaped 35.5% to $1.45 after the company reported that its AML treatment liposomal annamycin has been awarded the FDA Orphan Drug designation. Share volume was 11.1 million, compared to an all-day average of 415,000
